{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:25:09Z","timestamp":1789593909393,"version":"build-2803163510"},"reference-count":85,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"vor","delay-in-days":43,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.canrad.2026.104833","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T18:49:57Z","timestamp":1786128597000},"page":"104833","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Organs at risk radiation dose constraints: 2025 update"],"prefix":"10.1016","volume":"30","author":[{"given":"Georges","family":"No\u00ebl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Ailloud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Vendrely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrus","family":"Chargari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Khalifa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoann","family":"Pointreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Antoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina","family":"Lekhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Latorzeff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.canrad.2026.104833_bib0430","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.radonc.2014.01.018","article-title":"Impact of postoperative intensity modulated radiotherapy on acute gastro-intestinal toxicity for patients with endometrial cancer: results of the phase II RTCMIENDOMETRE French multicentre trial","volume":"111","author":"Barillot","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2026.104833_bib0435","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1748-717X-8-112","article-title":"Contribution of three-dimensional conformal intensity-modulated radiation therapy for women affected by bulky stage II supradiaphragmatic Hodgkin disease","volume":"8","author":"Antoni","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.canrad.2026.104833_bib0440","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.radonc.2008.12.016","article-title":"Can we reduce the incidence of second primary malignancies occurring after radiotherapy? A critical review","volume":"91","author":"Tubiana","year":"2009","journal-title":"Radiother Oncol"},{"issue":"11","key":"10.1016\/j.canrad.2026.104833_bib0445","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1470-2045(13)70386-3","article-title":"The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials","volume":"14","author":"Haviland","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2026.104833_bib0450","doi-asserted-by":"crossref","first-page":"S200","DOI":"10.1016\/j.canrad.2016.07.037","article-title":"[Prostate cancer external beam radiotherapy]","volume":"20\u00a0Suppl","author":"de Crevoisier","year":"2016","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2026.104833_bib0455","first-page":"2660","article-title":"[Reference bases of radiotherapy under stereotaxic conditions for bronchopulmonary, hepatic, prostatic, upper aero-digestive, cerebral and bone tumors or metastases]","volume":"22","author":"Barillot","year":"2018","journal-title":"Cancer Radiother"},{"issue":"5","key":"10.1016\/j.canrad.2026.104833_bib0460","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.ijrobp.2017.08.014","article-title":"Hypofractionated stereotactic radiation therapy to the resection bed for intracranial metastases","volume":"99","author":"Keller","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.canrad.2026.104833_bib0465","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.canrad.2019.11.003","article-title":"Radiation-induced lung toxicity predictors: retrospective analysis of 90 patients treated with stereotactic body radiation therapy for stage I non-small-cell lung carcinoma","volume":"24","author":"Menoux","year":"2020","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2026.104833_bib0470","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.canrad.2012.07.179","article-title":"[Stereotactic radiotherapy of intracranial benign tumors]","volume":"16","author":"No\u00ebl","year":"2012","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2026.104833_bib0475","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/j.canrad.2011.02.008","article-title":"[Stereotactic radiotherapy for brain metastasis]","volume":"16\u00a0Suppl","author":"No\u00ebl","year":"2012","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2026.104833_bib0480","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.canrad.2020.06.013","article-title":"Role of radiation therapy in brain metastases management","volume":"24","author":"Dhermain","year":"2020","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2026.104833_bib0485","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.radonc.2019.03.034","article-title":"Development and internal validation of a multinomial NTCP model for the severity of acute dyspnea after radiotherapy for lung cancer","volume":"136","author":"Defraene","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2026.104833_bib0490","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.canrad.2019.07.144","article-title":"[Reirradiation of brain metastasis: review of the last five years]","volume":"23","author":"Nguyen","year":"2019","journal-title":"Cancer Radiother"},{"issue":"1","key":"10.1016\/j.canrad.2026.104833_bib0495","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13014-019-1262-8","article-title":"A systematic review of dose-volume predictors and constraints for late bowel toxicity following pelvic radiotherapy","volume":"14","author":"Jadon","year":"2019","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.canrad.2026.104833_bib0500","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.canrad.2010.02.008","article-title":"[Normal tissue tolerance to external beam radiation therapy: esophagus]","volume":"14","author":"Bera","year":"2010","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2026.104833_bib0505","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.canrad.2017.07.046","article-title":"[Lung dose constraints for normofractionated radiotherapy and for stereotactic body radiation therapy]","volume":"21","author":"Blais","year":"2017","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2026.104833_bib0510","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.canrad.2017.07.042","article-title":"[Doses to organs at risk in conformational and stereotactic body radiation therapy: liver]","volume":"21","author":"Debbi","year":"2017","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2026.104833_bib0515","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.canrad.2017.07.038","article-title":"[Doses to organs at risk for conformational and stereotactic radiotherapy: bladder]","volume":"21","author":"Duverg\u00e9","year":"2017","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2026.104833_bib0520","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.canrad.2017.08.108","article-title":"[Hippocampus, brainstem and brain dose-volume constraints for fractionated 3-D radiotherapy and for stereotactic radiation therapy: limits and perspectives]","volume":"21","author":"G\u00e9rard","year":"2017","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2026.104833_bib0525","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.canrad.2017.07.036","article-title":"[Dose constraints to organs at risk for conformational and stereotactic radiotherapy: small bowel and duodenum]","volume":"21","author":"Goupy","year":"2017","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2026.104833_bib0530","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.canrad.2014.03.009","article-title":"Robotic stereotactic body radiation therapy for tumors of the liver: radiation-induced liver disease, incidence and predictive factors","volume":"18","author":"Janoray","year":"2014","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2026.104833_bib0535","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.canrad.2017.07.028","article-title":"[Stereotactic body radiation therapy for hepatic malignancies: organs at risk, uncertainties margins, doses]","volume":"21","author":"Lacornerie","year":"2017","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2026.104833_bib0540","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.canrad.2017.06.005","article-title":"[Normal tissue tolerance to external beam radiation therapy: bone marrow and cortical bone structures]","volume":"21","author":"Schernberg","year":"2017","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2026.104833_bib0545","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.canrad.2017.07.044","article-title":"[Doses to organs at risk in conformational radiotherapy and stereotaxic irradiation: the heart]","volume":"21","author":"Vandendorpe","year":"2017","journal-title":"Cancer Radiother"},{"issue":"12","key":"10.1016\/j.canrad.2026.104833_bib0550","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.ebiom.2015.10.024","article-title":"Radiation-induced CD8 T-lymphocyte apoptosis as a predictor of breast fibrosis after radiotherapy: results of the prospective multicenter French trial","volume":"2","author":"Azria","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.canrad.2026.104833_bib0555","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.semradonc.2017.04.003","article-title":"Functional assays for individual radiosensitivity: a critical review","volume":"27","author":"Ferlazzo","year":"2017","journal-title":"Semin Radiat Oncol"},{"issue":"3","key":"10.1016\/j.canrad.2026.104833_bib0560","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1080\/09553002.2019.1665209","article-title":"Clinical and epidemiological observations on individual radiation sensitivity and susceptibility","volume":"96","author":"Seibold","year":"2020","journal-title":"Int J Radiat Biol"},{"key":"10.1016\/j.canrad.2026.104833_bib0565","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.semradonc.2017.04.005","article-title":"Radiogenomics: identification of genomic predictors for radiation toxicity","volume":"27","author":"Rosenstein","year":"2017","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.canrad.2026.104833_bib0570","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.semradonc.2017.04.001","article-title":"Mechanisms of normal tissue injury from irradiation","volume":"27","author":"Citrin","year":"2017","journal-title":"Semin Radiat Oncol"},{"issue":"2","key":"10.1016\/j.canrad.2026.104833_bib0575","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ijrobp.2019.05.064","article-title":"Impact of radiation dose to the host immune system on tumor control and survival for stage III non\u2013small cell lung cancer treated with definitive radiation therapy","volume":"105","author":"Ladbury","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.canrad.2026.104833_bib0580","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3109\/0284186X.2013.820341","article-title":"Towards individualized dose constraints: adjusting the QUANTEC radiation pneumonitis model for clinical risk factors","volume":"53","author":"Appelt","year":"2014","journal-title":"Acta Oncol"},{"key":"10.1016\/j.canrad.2026.104833_bib0585","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3389\/fonc.2019.00877","article-title":"Radiation-induced lung injury (RILI)","volume":"9","author":"Giuranno","year":"2019","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.canrad.2026.104833_bib0590","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.clon.2020.07.005","article-title":"Skin toxicity in early breast cancer patients treated with field-in-field breast intensity-modulated radiotherapy versus helical inverse breast intensity-modulated radiotherapy: results of a phase III randomised controlled trial","volume":"33","author":"Joseph","year":"2021","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.canrad.2026.104833_bib0595","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ijrobp.2006.05.009","article-title":"Limitations of the planning organ at risk volume (PRV) concept","volume":"66","author":"Stroom","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2026.104833_bib0600","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1016\/j.ijrobp.2012.09.021","article-title":"Utility of normal tissue-to-tumor \u03b1\/\u03b2 ratio when evaluating isodoses of isoeffective radiation therapy treatment plans","volume":"85","author":"Gay","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2026.104833_bib0605","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.semradonc.2008.04.004","article-title":"The linear-quadratic model is an appropriate methodology for determining isoeffective doses at large doses per fraction","volume":"18","author":"Brenner","year":"2008","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.canrad.2026.104833_bib0610","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.semradonc.2008.04.005","article-title":"The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery","volume":"18","author":"Kirkpatrick","year":"2008","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.canrad.2026.104833_bib0615","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.radonc.2020.07.033","article-title":"Reirradiation in the thorax\u00a0\u2013\u00a0an analysis of efficacy and safety based on accumulated EQD2 doses","volume":"152","author":"Schr\u00f6der","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2026.104833_bib0620","doi-asserted-by":"crossref","first-page":"110184","DOI":"10.1016\/j.radonc.2024.110184","article-title":"Multicentre evaluation of variation in cumulative dose assessment in reirradiation scenarios","volume":"194","author":"Hardcastle","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2026.104833_bib0625","doi-asserted-by":"crossref","first-page":"109585","DOI":"10.1016\/j.radonc.2023.109585","article-title":"Challenges of re-irradiation: a call to arms for physicists\u00a0\u2013\u00a0and radiotherapy vendors","volume":"182","author":"Vasquez Osorio","year":"2023","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.canrad.2026.104833_bib0630","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ijrobp.2024.12.023","article-title":"Software support tools for reirradiation: a report from Reirradiation Collaborative Group (ReCOG) 2024","volume":"122","author":"Matrosic","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.canrad.2026.104833_bib0635","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.canrad.2024.08.002","article-title":"Tumor reirradiation: issues, challenges and perspectives for radiobiology","volume":"28","author":"No\u00ebl","year":"2024","journal-title":"Cancer Radiother"},{"issue":"3","key":"10.1016\/j.canrad.2026.104833_bib0640","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.ijrobp.2004.06.016","article-title":"Proposal of human spinal cord reirradiation dose based on collection of data from 40 patients","volume":"61","author":"Nieder","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.canrad.2026.104833_bib0645","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1053\/srao.2000.6593","article-title":"Tissue tolerance to reirradiation","volume":"10","author":"Nieder","year":"2000","journal-title":"Semin Radiat Oncol"},{"issue":"6","key":"10.1016\/j.canrad.2026.104833_bib0650","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00066-021-01772-7","article-title":"New clinical data on human spinal cord re-irradiation tolerance","volume":"197","author":"Doi","year":"2021","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.canrad.2026.104833_bib0655","doi-asserted-by":"crossref","first-page":"109663","DOI":"10.1016\/j.radonc.2023.109663","article-title":"ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma","volume":"184","author":"Niyazi","year":"2023","journal-title":"Radiother Oncol"},{"issue":"4","key":"10.1016\/j.canrad.2026.104833_bib0660","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.ijrobp.2010.01.039","article-title":"Hippocampal-sparing whole-brain radiotherapy: a \u201chow-to\u201d technique using helical tomotherapy and linear accelerator-based intensity-modulated radiotherapy","volume":"78","author":"Gondi","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.canrad.2026.104833_bib0665","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.clon.2022.02.010","article-title":"UK 2022 consensus on normal tissue dose-volume constraints for oligometastatic, primary lung and hepatocellular carcinoma stereotactic ablative radiotherapy","volume":"34","author":"Diez","year":"2022","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"23","key":"10.1016\/j.canrad.2026.104833_bib0670","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.3390\/cancers13236086","article-title":"Dose\u2013response effect and dose\u2013toxicity in stereotactic radiotherapy for brain metastases: a review","volume":"13","author":"Loo","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canrad.2026.104833_bib0675","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.radonc.2020.07.037","article-title":"The Danish Head and Neck Cancer Group (DAHANCA) 2020 radiotherapy guidelines","volume":"151","author":"Jensen","year":"2020","journal-title":"Radiother Oncol"},{"issue":"5","key":"10.1016\/j.canrad.2026.104833_bib0680","first-page":"1166","article-title":"International guideline on dose prioritization and acceptance criteria in radiation therapy planning for nasopharyngeal carcinoma","volume":"105","author":"Anon","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2026.104833_bib0685","series-title":"Cancer survivorship","article-title":"Overview of important \u201corgans at risk\u201d (oar) in modern radiotherapy for head and neck cancer (HNC)","author":"Basu","year":"2019"},{"key":"10.1016\/j.canrad.2026.104833_bib0690","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.radonc.2020.11.014","article-title":"ESTRO ACROP guideline for target volume delineation of skull base tumors","volume":"156","author":"Combs","year":"2021","journal-title":"Radiother Oncol"},{"issue":"8","key":"10.1016\/j.canrad.2026.104833_bib0695","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S1470-2045(17)30318-2","article-title":"Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial","volume":"18","author":"Faivre-Finn","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2026.104833_bib0700","doi-asserted-by":"crossref","first-page":"110837","DOI":"10.1016\/j.radonc.2025.110837","article-title":"Diagnosis and treatment of radiation induced pneumonitis in patients with lung cancer: an ESTRO clinical practice guideline","volume":"207","author":"Ruysscher","year":"2025","journal-title":"Radiother Oncol"},{"issue":"17","key":"10.1016\/j.canrad.2026.104833_bib0705","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1016\/j.ejca.2014.07.009","article-title":"SOCCAR: A randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III non-small cell lung cancer and good performance status","volume":"50","author":"Maguire","year":"2014","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.canrad.2026.104833_bib0710","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.ijrobp.2024.03.050","article-title":"Stereotactic radiation for ultra-central non-small cell lung cancer: a safety and efficacy trial (SUNSET)","volume":"120","author":"Giuliani","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"10.1016\/j.canrad.2026.104833_bib0715","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2024.3089","article-title":"Stereotactic vs. hypofractionated radiotherapy for inoperable stage I non-small cell lung cancer: the LUSTRE phase 3 randomized clinical trial","volume":"10","author":"Swaminath","year":"2024","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.canrad.2026.104833_bib0720","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ijrobp.2015.07.2260","article-title":"A randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer: NRG Oncology RTOG 0915 (NCCTG N0927)","volume":"93","author":"Videtic","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2026.104833_bib0725","doi-asserted-by":"crossref","first-page":"110591","DOI":"10.1016\/j.radonc.2024.110591","article-title":"Dose constraints in breast cancer radiotherapy. A critical review","volume":"202","author":"De Rose","year":"2025","journal-title":"Radiother Oncol"},{"issue":"11","key":"10.1016\/j.canrad.2026.104833_bib0730","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1470-2045(13)70386-3","article-title":"The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials","volume":"14","author":"Haviland","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2026.104833_bib0735","doi-asserted-by":"crossref","first-page":"110915","DOI":"10.1016\/j.radonc.2025.110915","article-title":"Patient- and clinician-assessed five-year normal tissue effects following one-week versus three-week axillary radiotherapy for breast cancer: results from the phase III FAST-Forward trial randomised nodal substudy","volume":"207","author":"Brunt","year":"2025","journal-title":"Radiother Oncol"},{"issue":"5","key":"10.1016\/j.canrad.2026.104833_bib0740","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","article-title":"Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (Unicancer-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Conroy","year":"2021","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.canrad.2026.104833_bib0745","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","article-title":"Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial","volume":"16","author":"Shapiro","year":"2015","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.canrad.2026.104833_bib0750","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.prro.2021.09.004","article-title":"External beam radiation therapy for primary liver cancers: an ASTRO clinical practice guideline","volume":"12","author":"Apisarnthanarax","year":"2022","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.canrad.2026.104833_bib0755","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.radonc.2020.07.052","article-title":"ESTRO ACROP guidelines for target volume definition in pancreatic cancer","volume":"154","author":"Brunner","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2026.104833_bib0760","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1118\/1.3438081","article-title":"Stereotactic body radiation therapy: the report of AAPM Task Group 101","volume":"37","author":"Benedict","year":"2010","journal-title":"Med Phys"},{"issue":"1","key":"10.1016\/j.canrad.2026.104833_bib0765","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ijrobp.2021.09.027","article-title":"A Story of hypofractionation and the table on the wall","volume":"112","author":"Timmerman","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.canrad.2026.104833_bib0770","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1120\/jacmp.v12i2.3368","article-title":"Dose\u2013tolerance limits and dose\u2013volume histogram evaluation for stereotactic body radiotherapy","volume":"12","author":"Grimm","year":"2011","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.canrad.2026.104833_bib0775","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S1470-2045(24)00020-2","article-title":"Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a nonrandomised phase 2 trial","volume":"25","author":"Siva","year":"2024","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.canrad.2026.104833_bib0780","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.ijrobp.2010.03.049","article-title":"70Gy versus 80Gy in localized prostate cancer: 5-year results of G\u00e9tug 06 randomized trial","volume":"80","author":"Beckendorf","year":"2011","journal-title":"Int J Radiat Oncol"},{"issue":"10","key":"10.1016\/j.canrad.2026.104833_bib0785","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.ctrv.2015.10.005","article-title":"Definition of lymph node areas for radiotherapy of prostate cancer: a critical literature review by the French genitourinary group and the French Association of Urology (G\u00e9tug-Afu)","volume":"41","author":"Sargos","year":"2015","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"10.1016\/j.canrad.2026.104833_bib0790","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.ijrobp.2009.07.1754","article-title":"Use of normal tissue complication probability models in the clinic","volume":"76","author":"Marks","year":"2010","journal-title":"Int J Radiat Oncol"},{"issue":"5","key":"10.1016\/j.canrad.2026.104833_bib0795","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/j.ijrobp.2018.08.015","article-title":"A systematic post-QUANTEC review of tolerance doses for late toxicity after prostate cancer radiation therapy","volume":"102","author":"Olsson","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10338","key":"10.1016\/j.canrad.2026.104833_bib0800","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/S0140-6736(21)01790-6","article-title":"The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial","volume":"399","author":"Pollack","year":"2022","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.canrad.2026.104833_bib0805","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.20.03282","article-title":"Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase III randomized controlled trial","volume":"39","author":"Murthy","year":"2021","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.canrad.2026.104833_bib0810","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer","volume":"35","author":"Catton","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.canrad.2026.104833_bib0815","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.canrad.2017.11.004","article-title":"Dose constraints for moderate hypofractionated radiotherapy for prostate cancer: the French Genitourinary Group (G\u00e9tug) recommendations","volume":"22","author":"Langrand-Escure","year":"2018","journal-title":"Cancer Radiother"},{"issue":"10260","key":"10.1016\/j.canrad.2026.104833_bib0820","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(20)31553-1","article-title":"Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial","volume":"396","author":"Parker","year":"2020","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.canrad.2026.104833_bib0825","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer","volume":"391","author":"Van As","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2026.104833_bib0830","first-page":"48","article-title":"The EMBRACE II study: the outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies","volume":"9","author":"P\u00f6tter","year":"2018","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.canrad.2026.104833_bib0835","first-page":"1","article-title":"A practical approach to bladder preservation with hypofractionated radiotherapy for localised muscle-invasive bladder cancer","volume":"31","author":"Portner","year":"2021","journal-title":"Clin Transl Radiat Oncol"},{"issue":"1","key":"10.1016\/j.canrad.2026.104833_bib0840","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ijrobp.2021.08.008","article-title":"Long-term outcomes of NRG Oncology\/RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in anal canal cancer","volume":"112","author":"Kachnic","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.canrad.2026.104833_bib0845","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3109\/0284186X.2011.564650","article-title":"Bone marrow-sparing intensity-modulated radiation therapy for stage I seminoma","volume":"50","author":"Zilli","year":"2011","journal-title":"Acta Oncol"},{"key":"10.1016\/j.canrad.2026.104833_bib0850","first-page":"100902","article-title":"Brain radiotherapy and dorsal vagal complex irradiation: a new organ at risk to decrease radiation-induced nausea and vomiting?","volume":"51","author":"Caspar","year":"2024","journal-title":"Clin Transl Radiat Oncol"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321826000363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321826000363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:01:36Z","timestamp":1787756496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321826000363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":85,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1278321826000363"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2026.104833","relation":{},"ISSN":["1278-3218"],"issn-type":[{"value":"1278-3218","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Organs at risk radiation dose constraints: 2025 update","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2026.104833","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO).","name":"copyright","label":"Copyright"}],"article-number":"104833"}}